Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) shares shot up 7.9% on Friday . The company traded as high as $14.72 and last traded at $14.5250. 378,415 shares traded hands during trading, a decline of 73% from the average session volume of 1,408,402 shares. The stock had previously closed at $13.46.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on TRVI. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. Wall Street Zen cut shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. JonesTrading dropped their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, March 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Trevi Therapeutics currently has an average rating of “Buy” and a consensus target price of $22.90.
Read Our Latest Analysis on TRVI
Trevi Therapeutics Stock Performance
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). On average, research analysts anticipate that Trevi Therapeutics, Inc. will post -0.47 EPS for the current year.
Institutional Trading of Trevi Therapeutics
A number of large investors have recently made changes to their positions in TRVI. China Universal Asset Management Co. Ltd. increased its holdings in Trevi Therapeutics by 4.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company’s stock worth $195,000 after purchasing an additional 911 shares in the last quarter. Hilton Head Capital Partners LLC increased its holdings in Trevi Therapeutics by 32.6% during the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company’s stock worth $51,000 after purchasing an additional 1,044 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in Trevi Therapeutics by 20.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company’s stock worth $70,000 after purchasing an additional 1,300 shares in the last quarter. AlphaCentric Advisors LLC increased its holdings in Trevi Therapeutics by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company’s stock worth $286,000 after purchasing an additional 1,303 shares in the last quarter. Finally, Kennedy Capital Management LLC increased its holdings in Trevi Therapeutics by 2.4% during the 4th quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock worth $704,000 after purchasing an additional 1,336 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.
Trevi Therapeutics Company Profile
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.
Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.
Read More
- Five stocks we like better than Trevi Therapeutics
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
- ERock IPO: A $1.3B Power Play Solution
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
